All In Biotech

Drug Trial Radar · NCT07164287

Retrospective Observational Study of Intensity Effects in Psychedelic-assisted Treatment

Last checked: Nov 19, 2026Latest source record: Oct 2, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

376

Planned (sponsor's estimate)

Start

Jun 1, 2020

Primary completion

Apr 30, 2025

Study completion Sep 30, 2025

Sponsor

Lead sponsor
University Hospital, GenevaAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Sep 10, 2025

More drug trials from this sponsor

Design

Study type
Observational
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This retrospective observational study examines the effects of psychedelic-assisted psychotherapy (PAP) with lysergic acid diethylamide (LSD) or psilocybin in patients with treatment-resistant depressive, anxiety, or addictive disorders. Data will be analyzed from patients treated at the University Hospitals of Geneva between June 2020 and April 2025 who obtained individual authorizations from the Swiss Federal Office of Public Health for use of LSD or psilocybin under compassionate use criteria. The main objective is to assess the effects of psychedelic-assisted psychotherapy with LSD or psilocybin on changes in depressive symptoms, anxiety symptoms. Secondary objectives include evaluating the association between psychedelic session intensity and the administered dose of LSD or psilocybin, changes in depressive symptoms, anxiety symptoms, and problematic substance use, as well as their association with intensity effects. Additionally physiological effects during session will be assessed. All data are retrospectively collected from clinical records with prior patient consent. This study aims to generate evidence on the feasibility, safety, and therapeutic potential of PAP in real-world clinical practice.

Conditions

  • Major Depressive Disorder (MDD)
  • Anxiety Disorders
  • Substance Use Disorder (SUD)
  • PTSD - Post Traumatic Stress Disorder

Interventions

  • Lysergic Acid Diethylamide (LSD) or psilocybinDrug

    Psychedelic-assisted psychotherapy with LSD or psilocybin as a part of a clinical routine in our department

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Self-reported depressive symptoms (BDI-II)Time frame: Baseline and 1 month after each psychedelic treatment session (sessions 1-3, up to 12 months)
  2. Self-reported symptoms of anxiety (STAI)Time frame: Baseline and 1 month after each psychedelic treatment session (sessions 1-3, up to 12 months)

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Geneva University Hospital

    Geneva, Switzerland

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.